234 related articles for article (PubMed ID: 15663994)
1. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
3. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?
Mulholland DJ; Dedhar S; Coetzee GA; Nelson CC
Endocr Rev; 2005 Dec; 26(7):898-915. PubMed ID: 16126938
[TBL] [Abstract][Full Text] [Related]
4. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
5. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells.
Weigel NL
Nutr Rev; 2007 Aug; 65(8 Pt 2):S116-7. PubMed ID: 17867385
[No Abstract] [Full Text] [Related]
6. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.
Tokar EJ; Webber MM
Clin Exp Metastasis; 2005; 22(3):275-84. PubMed ID: 16158255
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D in prostate cancer.
Trump DL; Aragon-Ching JB
Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and prostate cancer: biologic interactions and clinical potentials.
Miller GJ
Cancer Metastasis Rev; 1998-1999; 17(4):353-60. PubMed ID: 10453279
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signaling in prostate cancer.
Culig Z; Santer FR
Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
[TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
13. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
14. Advances in the development of retinoids as chemopreventive agents.
Lippman SM; Lotan R
J Nutr; 2000 Feb; 130(2S Suppl):479S-482S. PubMed ID: 10721933
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic concepts in androgen-dependence of prostate cancer.
Craft N; Sawyers CL
Cancer Metastasis Rev; 1998-1999; 17(4):421-7. PubMed ID: 10453286
[TBL] [Abstract][Full Text] [Related]
16. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.
Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ
Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759
[TBL] [Abstract][Full Text] [Related]
17. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
19. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer.
Peehl DM; Krishnan AV; Feldman D
J Nutr; 2003 Jul; 133(7 Suppl):2461S-2469S. PubMed ID: 12840225
[TBL] [Abstract][Full Text] [Related]
20. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]